Cover Image
市場調查報告書

全球高磷酸鹽血症治療藥市場考察,機會分析,市場佔有率,預測

Global Hyperphosphatemia Drugs Market Insights, Opportunities, Analysis, Market Shares and Forecast 2016 - 2022

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 358656
出版日期 內容資訊 英文 140 Pages
商品交期: 請詢問到貨日
價格
Back to Top
全球高磷酸鹽血症治療藥市場考察,機會分析,市場佔有率,預測 Global Hyperphosphatemia Drugs Market Insights, Opportunities, Analysis, Market Shares and Forecast 2016 - 2022
出版日期: 2016年05月24日 內容資訊: 英文 140 Pages
簡介

全球高磷酸鹽血症治療藥市場,2016年∼2022年之間預期有高成長。尤其是亞太地區有非常大的突破。

本報告提供全球高磷酸鹽血症治療藥市場相關調查分析,市場概要,市場決策要素,各部門分析,市場區隔,競爭情形,各地區分析,企業簡介等系統性資訊。

第1章 簡介

第2章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 參數分析
  • 主要市場考察
  • 競爭情形
  • 五力分析模型
  • 主要的購買標準
  • 策略性建議
  • 策略性結論

第3章 市場決策要素

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 市場課題
  • 親市場
  • 競爭市場
  • 替代市場

第4章 市場區隔

  • 各適應症
  • 各醫療

第5章 各地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 其他
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳洲
    • 其他
  • 其他

第6章 企業簡介

  • BIOTECH PHARMACAL
  • BRUNO FARMACEUTICI SPA
  • CIPLA
  • DM PHARMA
  • DSM
  • FERMENTA BIOTECH LTD.
  • JOHNSON & JHONSON
  • MOORE DRUGS CO.
  • PFIZER
  • ROCHE
  • SIEMENS
  • SUN PHARM INC
  • ULTRAGENYX
  • UPJOHN
  • Geria新藥工業

圖表

目錄
Product Code: HPH-1611015

Hyperphosphatemia predicted in patients who have an antiquity of starvation, anorexia/bulimia, alcoholism. Adequate cure comprises phosphate supplements along with feeding and care to causal eating disorders or substance exploitation. The global Hyperphosphatemia drugs market is driven by increasing aging population. According to WHO the world aged population by the end of 2050 is expected to reach 2 billion that is 900 million in 2015. Now Around 125 million people aged 80 years or more. By the end of 2050 almost 125 million people aged 80 years or more is expected to reach in China alone and 434 million people across the globe. Approximately 80% people live in low and middle income countries by the end of 2050. As the increasing aging population is one of the major driving factor of global Hyperphosphatemia drugs market.

The global Hyperphosphatemia drugs market is estimated to see new heights during the forecasted period. The stringent government regulations and presence of alternatives are hampering the growth of Hyperphosphatemia drugs in the global market. The untapped APAC region is creating the huge opportunities for the forecasted period in global Hyperphosphatemia drugs market.

The Hyperphosphatemia drugs is segmented on the basis of application, medical care and geography. The application segment is segmented into mineral supplements, vitamin D preparation and calcimimetic drugs. Medical care segment is further segmented into cause, severity and duration.

The global Hyperphosphatemia drugs market is driven by the presence of some the prominent player in the market. Biotech Pharmacal, Cipla, DM Pharma, DSM, Johnson & Jhonson, Pfizer, Sun Pharm Inc. and UltraGenyx. The mergers, acquisition, innovation, product development are the key strategies adopted by key players to sustain into competitive market. may 11, 2016, Johnson & Johnson opens JLABS in Torronto, in which they are providing offoces, modular labs, access to industry capital funding. In this JLABS facility provide accommodations 50 startups and opens with 22 companies dealing in various sector in healthcare drug innovation.

On the basis of geography North America, Europe, Asia Pacific and RoW are the major segments. The Asia Pacific dominates the Hyperphosphatemia drugs market with holding the largest market share. The large share is dominated by increasing aging population in the region. The rising osteoporosis in the APAC region is also driving the growth in the APAC market. the North America is the fastest growing region in the global market. the growth is majorly driven by the changing dietary habits in the region and increasing osteoporosis in the North America region.

Table of Contents

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. MARKET DEFINITION AND SCOPE
  • 2.2. KEY FINDINGS
  • 2.3. PARAMETRIC ANALYSIS
    • 2.3.1. RAW MATERIAL SUPPLIER
    • 2.3.2. PRODUCTION GEOGRAPHICALLY
    • 2.3.3. ADOPTION ACROSS VARIOUS INDUSTRIES
  • 2.4. KEY MARKET INSIGHTS
    • 2.4.1. TOP 3 EMERGING COUNTRIES
    • 2.4.2. TOP 3 REVENUE GENERATING SEGMENTS
    • 2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS
    • 2.4.4. TOP 3 GEOGRAPHY
  • 2.5. COMPETITIVE LANDSCAPE
    • 2.5.1. MARKET SHARE ANALYSIS
    • 2.5.2. TOP WINNING STRATEGIES
    • 2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
  • 2.6. PORTER'S FIVE FORCE MODEL
    • 2.6.1. THREAT OF NEW ENTRANTS
    • 2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 2.6.3. BARGAINING POWER OF BUYER
    • 2.6.4. BARGAINING POWER OF SUPPLIER
    • 2.6.5. INTENSITY OF COMPETITIVE RIVALRY
  • 2.7. KEY BUYING CRITERIA
  • 2.8. STRATEGIC RECOMMENDATION
  • 2.9. STRATEGIC CONCLUSIONS

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. RISING AGING POPULATION
    • 3.1.2. INCREASING OSTEOPOROSIS
    • 3.1.3. CHANGING DIETARY HABITS
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. STRINGENT FDA REGULATION
    • 3.2.2. PRESENCE OF ALTERNATIVES
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. UNTAPPED APAC REGIONS
  • 3.4. MARKET CHALLENGES
    • 3.4.1. SIDE EFFECTS ASSOCIATED WITH DRUGS
  • 3.5. PARENT MARKET
  • 3.6. COMPETITORS MARKET
  • 3.7. ALTERNATIVE MARKET

4. MARKET SEGMENTATION

  • 4.1. BY APPLICATION
    • 4.1.1. GLOBAL MINERAL SUPPLEMENTS MARKET, 2014-2022 ($MILLIONS)
    • 4.1.2. GLOBAL VITAMIN D PREPARATION MARKET,2014-2022 ($MILLIONS)
    • 4.1.3. GLOBAL CALCIMIMETIC DRUGS MARKET,2014-2022 ($MILLIONS)
  • 4.2. BY MEDICAL CARE
    • 4.2.1. GLOBAL CAUSE MARKET, 2014-2022 ($MILLIONS)
    • 4.2.2. GLOBAL SEVERITY MARKET,2014-2022 ($MILLIONS)
    • 4.2.3. GLOBAL DURATION MARKET,2014-2022 ($MILLIONS)

5. GEOGRAPHICAL ANALYSIS

  • 5.1. NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.1.1. UNITED STATES (U.S.) HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.1.2. CANADA HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
  • 5.2. EUROPE HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.2.1. UNITED KINGDOM (UK) HYPERPHOSPHATEMIA DRUGS MARKET, 2014-2022 ($MILLIONS)
    • 5.2.2. FRANCE HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.2.3. GERMANY HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.2.4. SPAIN HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.2.5. ITALY HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.2.6. ROE HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
  • 5.3. ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.3.1. INDIA HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.3.2. CHINA HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.3.3. JAPAN HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.3.4. AUSTRALIA HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.3.5. ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
  • 5.4. REST OF THE WORLD HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022,($MILLIONS)
    • 5.4.1. LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.4.2. MENA HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)
    • 5.4.3. AFRICA HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022 ($MILLIONS)

6. COMPANY PROFILING: - (OVER, SCOT ANALYSIS, STRATEGIC REVIEW)

  • 1. BIOTECH PHARMACAL
  • 2. BRUNO FARMACEUTICI SPA
  • 3. CIPLA
  • 4. DM PHARMA
  • 5. DSM
  • 6. FERMENTA BIOTECH LTD.
  • 7. JOHNSON & JHONSON
  • 8. MOORE DRUGS CO.
  • 9. PFIZER
  • 10. ROCHE
  • 11. SIEMENS
  • 12. SUN PHARM INC
  • 13. ULTRAGENYX
  • 14. UPJOHN
  • 15. ZERIA PHARMACEUTICAL

LIST OF TABLES

  • 1. GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY APPLICATION, 2014-2022 ($MILLIONS)
  • 2. GLOBAL MINERAL SUPPLEMENTS MARKET, 2014-2022 ($MILLIONS)
  • 3. GLOBAL VITAMIN D PREPARATION MARKET,2014-2022 ($MILLIONS)
  • 4. GLOBAL CALCIMIMETIC DRUGS MARKET,2014-2022 ($MILLIONS)
  • 5. GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY MEDICAL CARE, 2014-2022 ($MILLIONS)
  • 6. GLOBAL CAUSE MARKET, 2014-2022 ($MILLIONS)
  • 7. GLOBAL SEVERITY MARKET,2014-2022 ($MILLIONS)
  • 8. GLOBAL DURATION MARKET,2014-2022 ($MILLIONS)
  • 9. NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022, ($MILLIONS)
  • 10. EUROPE HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022, ($MILLIONS)
  • 11. ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022, ($MILLIONS)
  • 12. REST OF THE WORLD HYPERPHOSPHATEMIA DRUGS MARKET,2014-2022, ($MILLIONS)

LIST OF FIGURES

  • 1. GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY APPLICATION, 2014-2022 ($MILLIONS)
  • 2. GLOBAL MINERAL SUPPLEMENTS MARKET, 2014-2022 ($MILLIONS)
  • 3. GLOBAL VITAMIN D PRECREATION MARKET,2014-2022 ($MILLIONS)
  • 4. GLOBAL CALCIMIMETIC DRUGS MARKET,2014-2022 ($MILLIONS)
  • 5. GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY MEDICAL CARE, 2014-2022 ($MILLIONS)
  • 6. GLOBAL CAUSE MARKET, 2014-2022 ($MILLIONS)
  • 7. GLOBAL SEVERITY MARKET,2014-2022 ($MILLIONS)
  • 8. GLOBAL DURATION MARKET,2014-2022 ($MILLIONS)
Back to Top